SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Diabetologia

Volumn 61, Issue 10, 2018, Pages 2108-2117

  Verma, Subodh ^a   McMurray, John J V ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular effects; Heart failure; Mechanisms; Review; SGLT2 inhibitors

Indexed keywords

ADIPOCYTOKINE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

BIOENERGY; CARDIAC MUSCLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART STRESS; HEART VENTRICLE FUNCTION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THEMATIC ANALYSIS; TRANSLATIONAL RESEARCH; ANIMAL; COMPLICATION; DIABETIC COMPLICATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART; HEART VENTRICLE; KIDNEY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PHARMACOLOGY;

ADIPOKINES; ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART; HEART VENTRICLES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85052558182     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4670-7     Document Type: Review

References (66)

1. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
2. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
3. Verma S, Mazer CD, Fitchett D et al (2018) Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia 61:1712–1723
4. Fitchett D, Butler J, van de Borne P et al (2018) Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 39:363–370
5. Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37:1526–1534
6. Rådholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 10.1161/CIRCULATIONAHA.118.034222
7. Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940
8. Jorsal A, Wiggers H, McMurray JJV (2018) Heart failure: epidemiology, pathophysiology, and management of heart failure in diabetes mellitus. Endocrinol Metab Clin N Am 47:117–135
9. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA (2014) Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2:843–851
10. Seferovic PM, Petrie MC, Filippatos GS et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 10.1002/ejhf.1170
11. Greene SJ, Vaduganathan M, Khan MS et al (2018) Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol 71:1379–1390
12. Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122:624–638
13. Seferovic PM, Paulus WJ (2015) Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36:1718–1727
14. Farkouh ME, Verma S (2018) Prevention of heart failure with SGLT2 inhibition: insights from CVD-REAL. J Am Coll Cardiol (in press)
15. Swoboda PP, McDiarmid AK, Erhayiem B et al (2017) Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc 6:e005539
16. Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136:249–259
17. Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137:323–334
18. Kosiborod M, Lam CSP, Kohsaka S et al (2018) Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol. 10.1016/j.jacc.2018.03.009
19. Boonman-de Winter LJ, Rutten FH, Cramer MJ et al (2012) High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 55:2154–2162
20. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339
21. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136:1643–1658
22. Fitchett D, McKnight J, Lee J et al (2017) Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C), and HbA1c. Diabetes 66:A312–A313 Abstract
23. Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129
24. Al-Jobori H, Daniele G, Cersosimo E et al (2017) Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes 66:1999–2006
25. Heise T, Seewaldt-Becker E, Macha S et al (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeksʼ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613–621
26. Seman L, Macha S, Nehmiz G et al (2013) Empagliflozin (BI 10773), a potent and selective sglt2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2:152–161
27. Byrne NJ, Parajuli N, Levasseur JL et al (2017) Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC: Basic Translational Sci 1:347–354
28. Shi X, Verma S, Yun J et al (2017) Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem 433:97–102
29. Butler J, Hamo CE, Filippatos G et al (2017) The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 19:1390–1400
30. Karg MV, Bosch A, Kannenkeril D et al (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol 17:5
31. Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356–363
32. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862
33. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479–487
34. Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC (2018) Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc 7:e007046
35. Striepe K, Jumar A, Ott C et al (2017) Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation 136:1167–1169
36. Chilton R, Tikkanen I, Cannon CP et al (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180–1193
37. Li H, Shin SE, Seo MS et al (2018) The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci 197:46–55
38. Solini A, Giannini L, Seghieri M et al (2017) Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 16:138
39. Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME Trial: a “Thrifty Substrate” hypothesis. Diabetes Care 39:1108–1114
40. Lopaschuk GD, Verma S (2016) Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24:200–202
41. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258
42. Mizuno Y, Harada E, Nakagawa H et al (2017) The diabetic heart utilizes ketone bodies as an energy source. Metabolism 77:65–72
43. Gormsen LC, Svart M, Thomsen HH et al (2017) Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc 6:e005066
44. Santos-Gallego CG, Ibanez JAR, San Antonio R et al (2018) Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility. J Am Coll Cardiol 71:A674 Abstract
45. Kappel BA, Lehrke M, Schutt K et al (2017) Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation 136:969–972
46. Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2:1025–1029
47. + and vasodilation. Diabetologia 61:722–726
48. + exchanger in rats and rabbits. Diabetologia 60:568–573
49. Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89
50. Fedak PW, Verma S, Weisel RD, Li RK (2005) Cardiac remodeling and failure from molecules to man (part II). Cardiovasc Pathol 14:49–60
51. Lee TM, Chang NC, Lin SZ (2017) Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104:298–310
52. Kang S, Verma S, Teng G et al (2017) Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG Outcome. Can J Cardiol 33:S169 Abstract
53. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288:H2031–H2041
54. Patel VB, Shah S, Verma S, Oudit GY (2017) Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 22:889–902
55. Packer M (2018) Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 10.1111/dom.13229
56. Timothy Garvey W, Van Gaal L, Leiter LA et al (2018) Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 10.1016/j.metabol.2018.02.002
57. Sato T, Aizawa Y, Yuasa S et al (2018) The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 17:6
58. Verma S, Garg A, Yan AT et al (2016) Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 39:e212–e213
59. Singh JS, Fathi A, Vickneson K et al (2016) Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol 15:97
60. Januzzi JL Jr, Butler J, Jarolim P et al (2017) Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70:704–712
61. Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:e4–e5
62. Verma S, Mazer CD, Al-Omran M et al (2018) Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137:405–407
63. Sherman SE, Bell GI, Teoh H et al (2018) Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. JACC Basic Translational Sci 3:327–329
64. Verma S, Bhatt DL, Bain SC et al (2018) Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial. Circulation 137:2179–2183
65. Wiviott SD, Raz I, Bonaca MP et al (2018) The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE) – TIMI 58 Trial. Am Heart J 200:83–89
66. Jardine MJ, Mahaffey KW, Neal B et al (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study rationale, design, and baseline characteristics. Am J Nephrol 46:462–472